Edwards Lifesciences Corporation (EW)
$
82.45
-1.03 (-1.25%)
Key metrics
Financial statements
Free cash flow per share
1.0356
Market cap
43.8 Billion
Price to sales ratio
7.7081
Debt to equity
0.0666
Current ratio
4.6823
Income quality
0.1919
Average inventory
1.1 Billion
ROE
0.4122
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Edwards Lifesciences Corporation specializes in providing innovative products and technologies aimed at treating structural heart disease, as well as critical care and surgical monitoring solutions in various global markets including the United States, Europe, and Japan. The company recorded an operating income of $1,378,700,000.00 reflecting its earnings from core operations. It reported a substantial revenue of $5,439,500,000.00 showcasing its strong market presence in the industry. The company offers transcatheter heart valve replacement products, allowing for minimally invasive heart valve replacements, along with transcatheter valve repair and replacement products targeting mitral and tricuspid valve diseases. Additionally, the company provides the PASCAL and Cardioband transcatheter valve repair systems, which facilitate minimally-invasive therapies. In terms of surgical structural heart solutions, it offers solutions like the aortic surgical valve under the INSPIRIS name and KONECT RESILIA, a pre-assembled aortic tissue valved conduit designed for patients needing valve and root replacements alongside the ascending aorta. The HARPOON Beating Heart Mitral Valve Repair System is also available for patients suffering from degenerative mitral regurgitation. Furthermore, Edwards Lifesciences delivers critical care solutions including advanced hemodynamic monitoring systems that assess heart function and fluid status in surgical and intensive care settings, as well as the Acumen Hypotension Prediction Index software, which provides timely alerts to clinicians regarding dangerously low blood pressure. The company reported an income before tax of $1,548,100,000.00 showcasing its pre-tax profitability, and the operating income ratio stands at $0.25 indicating the company's operational profitability margin. In the financial market, the stock is reasonably priced at $74.41 appealing to a broad range of investors and reflecting the company’s robust standing. The stock has a high average trading volume of 4,535,270.00 indicating strong liquidity which can attract both new and seasoned investors. With a mid-range market capitalization of $48,406,395,000.00 the company continues to be a steady performer within its sector. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape while driving innovation and growth in the Healthcare sector.
Is Edwards Lifesciences Corporation (EW) a good investment?
Investing in Edwards Lifesciences Corporation (EW) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Edwards Lifesciences Corporation (EW)'s stock forecast?
Analysts predict Edwards Lifesciences Corporation stock to fluctuate between $64.89 (low) and $87.09 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Edwards Lifesciences Corporation's market capitalization?
As of 2025-10-31, Edwards Lifesciences Corporation's market cap is $48,406,395,000, based on 587,100,000 outstanding shares.
How does Edwards Lifesciences Corporation compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Edwards Lifesciences Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Edwards Lifesciences Corporation (EW) stock?
To buy Edwards Lifesciences Corporation (EW) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for EW. Place an order (Market, Limit, etc.).
What is the best time to invest in Edwards Lifesciences Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Edwards Lifesciences Corporation stock ever split?
Edwards Lifesciences Corporation's last stock split was 3:1 on 2020-06-01.
How did Edwards Lifesciences Corporation perform in the last earnings report?
Revenue: $5,439,500,000 | EPS: $6.98 | Growth: 202.16%.
Where can I find Edwards Lifesciences Corporation's investor relations reports?
Visit https://www.edwards.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Edwards Lifesciences Corporation?
You can explore historical data from here
What is the all-time high and low for Edwards Lifesciences Corporation stock?
All-time high: $131.73 (2021-12-30) | All-time low: $58.93 (2024-07-25).
What are the key trends affecting Edwards Lifesciences Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Edwards Lifesciences Corporation ( EW ) Q3 2025 Earnings Call October 30, 2025 5:00 PM EDT Company Participants Mark Wilterding - Vice President of Investor Relations Bernard Zovighian - CEO & Director Scott Ullem - Corporate VP & CFO Daniel Lippis - Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) Daveen Chopra - Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies Conference Call Participants Travis Steed - BofA Securities, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Matthew Taylor - Jefferies LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Presentation Operator Greetings, and welcome to the Edwards Lifesciences' Third Quarter 2025 Conference Call. [Operator Instructions] Please note, this conference is being recorded.
reuters.com
Edwards Lifesciences beat Wall Street estimates for third-quarter results on Thursday, driven by strong demand for its artificial heart valves and other medical devices, with shares rising about 3% in extended trading.
reuters.com
Edwards Lifesciences said on Thursday its Chief Financial Officer Scott Ullem will step down by mid-2026 and remain in an advisory role after a successor is named.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders. If you currently own Edwards stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more abou.
globenewswire.com
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW).
businesswire.com
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. One-year data from the ENCIRCLE single-arm pivotal trial achieved all primary and secondary endpoints for safety and effectiveness, with outcomes simultaneously published in The Lancet. Thirty-day data from the EVOQUE system STS/ACC TVT Registry, the largest real-world transcatheter tricuspid valve replacement.
businesswire.com
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical outcomes at one year, also demonstrate excellent long-term valve performance and durability. Separately, 10-year results from PARTNER 2 intermediate risk studies reinforce Edwards' leadership in setting the standard for lasting valve performance and excellent patien.
globenewswire.com
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW).
businesswire.com
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2025 after the market closes on Thursday October 30, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwa.
prnewswire.com
NEW YORK , Oct. 22, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW). If you currently own shares of Edwards stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=29704 for more information.
See all news
